Canine Immune-Mediated Skin Disease: Diagnostic and Management Approach

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Distinguishing immune-mediated skin disease from infectious dermatoses, endocrine disorders, or neoplasia is critical, with lesion pattern recognition guiding initial diagnostics like cytology and histopathology.
• Pemphigus complex, characterized by autoantibodies targeting desmogleins, and cutaneous lupus erythematosus, involving immune complex deposition at the dermoepidermal junction, are primary categories of canine autoimmune skin disease.
• Definitive diagnosis relies on histopathology of multiple biopsy samples from early primary lesions, often supplemented by cytology for acantholytic cells and neutrophils, and serologic testing (e.g., antinuclear antibody) for systemic lupus erythematosus.
• Glucocorticoids are the first-line immunosuppressive therapy for induction, often combined with adjunctive agents like mycophenolate mofetil to achieve remission, which typically occurs within 5-6 weeks with combination therapy.
• Comprehensive monitoring including complete blood counts, serum biochemistry, and urinalysis is essential at baseline and regular intervals to detect myelosuppression, hepatotoxicity, renal injury, and secondary infections associated with immunosuppressive treatment.
• Prognosis varies by specific diagnosis, with lifelong therapy often required for pemphigus foliaceus, while juvenile sterile granulomatous dermatitis and lymphadenitis generally has a favorable prognosis with a shorter treatment course.

Immune-mediated skin diseases in dogs encompass a heterogeneous group of disorders in which the immune system targets cutaneous structures, producing clinical signs that range from pustules and crusts to ulcers and alopecia. These conditions challenge the practitioner because their presentations overlap with infectious dermatoses, endocrine disease, and neoplasia. This article provides a systematic framework for diagnosing and managing immune-mediated skin disease in dogs, with emphasis on clinical pattern recognition, diagnostic testing, and immunosuppressive therapy selection. It is written for practicing veterinarians who require a structured approach to these often complex cases.

The diagnostic journey begins with a fundamental distinction: is the lesion pattern consistent with autoimmunity directed at skin components, or does it represent a hypersensitivity reaction to an environmental or parasitic trigger? Conditions such as pemphigus complex, cutaneous lupus erythematosus, and juvenile sterile granulomatous dermatitis and lymphadenitis fall into the former category, while canine atopic dermatitis represents the latter. The diagnostic reasoning process must also account for the reality that secondary bacterial infection frequently complicates the clinical picture, obscuring the underlying immune-mediated process.

This article covers the pathophysiologic basis of immune-mediated skin disease, a structured diagnostic approach including cytology, histopathology, and serologic testing, and a management framework that addresses both induction and maintenance of immunosuppression. Monitoring parameters, adverse effect profiles, and prognostic indicators are discussed where the evidence supports their use. The content assumes familiarity with basic dermatologic examination techniques and routine clinical pathology.

At a Glance

Pathophysiology of Cutaneous Autoimmunity

The skin is an immunologically active organ with resident populations of Langerhans cells, dermal dendritic cells, macrophages, and T lymphocytes. Immune-mediated skin disease arises when self-tolerance breaks down and effector cells target cutaneous autoantigens. The specific target determines the clinical phenotype. In pemphigus foliaceus, autoantibodies target desmoglein molecules in desmosomes, disrupting cell-to-cell adhesion in the superficial epidermis and producing pustules and crusts. In cutaneous lupus erythematosus, immune complex deposition at the dermoepidermal junction triggers inflammation, apoptosis of basal keratinocytes, and the characteriztic interface dermatitis seen histologically.

The innate immune system contributes substantially to disease expression. Neutrophils and macrophages provide signals that initiate and maintain cutaneous inflammation, and their recruitment to sites of autoantibody deposition amplifies tissue injury. This observation has therapeutic implications: agents that suppress lymphocyte function may not fully control disease if innate immune effector cells remain active. The local lesional microenvironment, including cytokine gradients and chemokine signals, determines whether inflammation remains localized or becomes systemic.

Experimental models have advanced understanding of these mechanisms. In one canine model, immunization with heparan sulphate, a component of the glomerular basement membrane, induced a syndrome resembling systemic lupus erythematosus with proteinuria, dermatitis, and positive antinuclear antibody titres above 1:128. Immunohistology of skin lesions demonstrated immunoglobulin M and complement deposition at the dermoepidermal junction, confirming the immune complex-mediated nature of the cutaneous manifestations. This model illustrates the link between autoantibody production, complement activation, and clinical skin disease.

Classification of Canine Immune-Mediated Skin Disease

Immune-mediated skin diseases in dogs are classified by the primary target of the immune response and the dominant histologic pattern. The major categories include autoimmune diseases directed at specific skin structures, immune-mediated diseases with systemic involvement, and sterile inflammatory conditions of uncertain pathogenesis.

The pemphigus complex represents the most common autoimmune skin disease in dogs. Pemphigus foliaceus is the most frequently diagnosed variant, characterized by superficial pustules that rupture easily, leaving crusts and erosions. The nasal planum, pinnae, and footpads are commonly affected. Pemphigus vulgaris is deeper and more severe, with acantholysis at the suprabasal layer producing oral ulcers and cutaneous erosions. Bullous pemphigoid targets the basement membrane zone and presents with tense vesicles and ulcers.

Cutaneous lupus erythematosus encompasses a spectrum from discoid lupus erythematosus, which typically affects the nasal planum with depigmentation and erosion, to systemic lupus erythematosus with multisystemic involvement. The diagnosis of systemic lupus erythematosus requires compatible clinical signs in multiple organ systems supported by serologic evidence of autoantibody production. The experimental model described above demonstrates that dermatitis, arthritis, and glomerulonephritis can coexist in this syndrome.

Juvenile sterile granulomatous dermatitis and lymphadenitis, also called sterile pyogranuloma syndrome, affects young dogs between 8 and 36 weeks of age. Affected dogs develop painful edema of the muzzle, blepharitis, and sterile pustules, with marked lymphadenomegaly and fever in most cases. Cytology reveals pyogranulomatous inflammation, and histopathology confirms the sterile nature of the lesions. This condition responds to glucocorticoid therapy but may relapse after treatment withdrawal.

Clinical Presentation and Pattern Recognition

The clinical history should establish the onset and progression of lesions, the presence of pruritus, systemic signs such as fever or lethargy, and the response to prior antimicrobial or anti-inflammatory therapy. Immune-mediated skin disease often follows a progressive course, whereas infectious dermatoses may show partial response to antibiotics. Pruritus is variable: pemphigus foliaceus may be pruritic, while discoid lupus erythematosus is typically nonpruritic.

Lesion distribution provides important diagnostic clues. Pemphigus foliaceus has a characteriztic facial distribution affecting the nasal planum, periocular skin, and pinnae, with footpad involvement in some cases. Discoid lupus erythematosus is often limited to the nasal planum and bridge of the nose. Juvenile sterile granulomatous dermatitis and lymphadenitis presents with a distinctive muzzle and periocular distribution in a young dog with fever and lymphadenopathy.

The regional frequency of immune-mediated skin disease varies geographically. Data from North American veterinary teaching hospitals collected in the 1980s identified immune-mediated skin disease among the ten most common dermatologic diagnoses, with higher frequencies in the northeastern United States. Regional variation in disease frequency may reflect genetic predisposition in certain breeds or environmental factors, although the underlying causes of these geographic differences remain incompletely characterized.

Diagnostic Testing and Confirmation

The diagnostic approach to suspected immune-mediated skin disease follows a deliberate sequence. Clinical pattern recognition narrows the differential list, but confirmation requires cytology, histopathology, and in selected cases immunologic testing. The order matters because each test informs the interpretation of the next.

Cytology: The First-Line Test

Cytologic evaluation of intact pustules, crusts, or exudate should precede biopsy in nearly every case. Pustular lesions yield the highest diagnostic value. A sterile 25-gauge needle is used to rupture an intact pustule, and the contents are spread gently onto a glass slide. Air-dried samples are stained with Diff-Quik or Wright-Giemsa.

The cytologic distinction between neutrophilic and eosinophilic inflammation is diagnostically meaningful. Pemphigus foliaceus typically shows nondegenerate neutrophils with acantholytic keratinocytes, often in clusters. Bacterial pyoderma produces degenerate neutrophils with intracellular bacteria. Eosinophilic infiltrates suggest hypersensitivity disorders, eosinophilic granuloma complex, or insect bite reactions. The presence of acantholytic cells without bacteria strongly supports an autoimmune process, although acantholysis can occasionally be seen in deep pyoderma.

Cytology of lymph node aspirates is indicated when peripheral lymphadenopathy accompanies skin lesions. In juvenile sterile granulomatous dermatitis and lymphadenitis, lymph node aspirates reveal pyogranulomatous inflammation, supporting the diagnosis before histopathology is performed juvenile sterile granulomatous dermatitis and lymphadenitis case series.

Skin Biopsy: Technique and Sample Selection

Biopsy is the definitive diagnostic step for most immune-mediated skin diseases. The quality of the sample determines the quality of the diagnosis. Multiple biopsy sites should be selected to represent different stages of lesion development. Primary lesions, intact pustules or vesicles, are preferred over secondary lesions such as ulcers or crusts. When intact pustules are unavailable, early crusts that still contain viable inflammatory cells may yield diagnostic information.

A 6 to 8 mm biopsy punch is appropriate for most lesions. Larger samples are required for lesions involving the deep dermis or panniculus. The biopsy should be placed at the edge of the lesion to include both affected and adjacent normal skin, which helps the pathologist assess the interface between inflamed and uninflamed tissue. Samples should be handled gently to avoid crush artifact, placed on filter paper to prevent curling, and fixed in 10% neutral buffered formalin at a ratio of at least 10 parts fixative to 1 part tissue.

Multiple biopsies from different sites are recommended. A minimum of three to five samples is standard practice. Samples from the muzzle, pinnae, nasal planum, and footpads are often more diagnostic in pemphigus foliaceus because these sites show characteriztic histologic changes even when lesions are subtle.

Histopathologic Patterns and Their Interpretation

The histopathologic diagnosis rests on identifying the dominant inflammatory pattern and its location within the skin. The major patterns relevant to immune-mediated disease include:

The pathologist should be provided with a complete clinical description including lesion distribution, duration, and response to prior therapy. Glucocorticoid administration within two to four weeks before biopsy can suppress the inflammatory infiltrate and obscure the diagnosis. If the patient has received immunosuppressive doses of glucocorticoids, biopsy should be delayed when clinically feasible.

Direct immunofluorescence testing on frozen tissue can demonstrate immunoglobulin and complement deposition at the dermal-epidermal junction. This technique is used primarily in research settings and for confirming lupus erythematosus. The experimental model of canine systemic lupus erythematosus has shown immunoglobulin M and complement deposition at the dermal-epidermal junction in affected skin, supporting the utility of this test in selected cases canine systemic lupus erythematosus model development. However, false-positive and false-negative results occur, and the test does not replace routine histopathology.

Ancillary Testing and Comorbidity Assessment

Complete Blood Count and Serum Biochemistry

A complete blood count and serum biochemistry panel are indicated in every patient with suspected immune-mediated skin disease. These tests serve three purposes. First, they identify concurrent systemic disease that may influence treatment selection. Second, they establish baseline values for monitoring immunosuppressive therapy. Third, they detect paraneoplastic or infectious triggers that may mimic or precipitate immune-mediated skin disease.

The antinuclear antibody test is reserved for patients with clinical signs suggesting systemic lupus erythematosus, including polyarthritis, glomerulonephritis, fever, or multisystemic involvement. A positive antinuclear antibody test at a titer of 1:128 or higher supports the diagnosis in the appropriate clinical context canine systemic lupus erythematosus model development. A negative test does not exclude cutaneous lupus erythematosus, which may be seronegative.

Bacterial and Fungal Culture

Bacterial culture and susceptibility testing should be performed when cytology suggests infection or when the patient has failed to respond to empirical antibiotics. Secondary bacterial pyoderma is common in immune-mediated skin disease and can complicate the clinical picture. Similarly, dermatophyte culture is indicated when crusting and scaling lesions are present, particularly in young dogs or dogs with a history of exposure to other animals.

Diagnostic Algorithm

The following sequence represents a practical approach to the patient with suspected immune-mediated skin disease:

1. Complete history and physical examination with lesion mapping and photography
2. Skin scraping and cytologic evaluation of pustules, crusts, and exudate
3. Dermatophyte culture when crusting or scaling predominates
4. Skin biopsy with multiple samples from representative lesions
5. Complete blood count, serum biochemistry, and urinalysis
6. Antinuclear antibody testing when systemic lupus erythematosus is suspected
7. Bacterial culture when infection is confirmed or suspected
8. Response to therapy as a diagnostic confirmation when histopathology is inconclusive

Treatment Selection and Monitoring

Induction Therapy

Glucocorticoids remain the first-line immunosuppressive agent for most immune-mediated skin diseases in dogs. Prednisolone or prednisone is administered at immunosuppressive doses, and the response is assessed within two to four weeks. The goal of induction therapy is rapid control of inflammation followed by gradual tapering to the lowest effective dose.

Patients that fail to respond adequately to glucocorticoids alone or that require prolonged high-dose therapy are candidates for adjunctive immunosuppressive agents. Mycophenolate mofetil has been evaluated as a secondary agent in dogs with immune-mediated skin disease. In a retrospective study of 14 dogs treated with mycophenolate mofetil in conjunction with glucocorticoids, complete remission was achieved in 8 cases and partial remission in 2 cases, with a mean time to remission of 5.7 weeks mycophenolate mofetil retrospective evaluation. Adverse effects included diarrhea, vomiting, and hematochezia, and therapy was discontinued in two cases because of diarrhea. These findings support the use of mycophenolate mofetil as a glucocorticoid-sparing agent, but they also emphasize the need for client education regarding gastrointestinal adverse effects.

Monitoring Parameters

Patients receiving immunosuppressive therapy require regular monitoring. The following parameters should be assessed at baseline and at intervals determined by the clinical course:

The frequency of monitoring should be increased when new clinical signs develop or when the dose of immunosuppressive medication is escalated. Gastrointestinal adverse effects require prompt attention because they may limit drug tolerance and compliance mycophenolate mofetil retrospective evaluation.

Tapering and Relapse Management

Once remission is achieved, glucocorticoid doses are tapered gradually over weeks to months. The taper should be slow, typically reducing the dose by 25% every two to four weeks. Relapse during tapering requires a return to the previous effective dose and a slower subsequent taper. Adjunctive agents such as mycophenolate mofetil may allow a more rapid glucocorticoid taper while maintaining disease control.

Prognosis and Client Communication

The prognosis for canine immune-mediated skin disease varies by diagnosis. Pemphigus foliaceus carries a guarded to fair prognosis with lifelong therapy often required. Discoid lupus erythematosus has a better prognosis and may respond to less aggressive immunosuppression. Juvenile sterile granulomatous dermatitis and lymphadenitis carries a favorable prognosis, with most dogs responding to a short course of glucocorticoids over three to eight weeks, although relapse occurred in one of ten cases in the published series juvenile sterile granulomatous dermatitis and lymphadenitis case series.

Client communication should address the expected duration of therapy, the potential for adverse effects, the financial commitment, and the possibility of relapse. Owners should be counseled that immunosuppressive therapy increases susceptibility to infection and that any new systemic signs warrant prompt evaluation. The decision to pursue aggressive immunosuppression should be made collaboratively, with clear discussion of the risks and benefits for the individual patient.

Complications and Failure Modes

Immunosuppressive therapy carries predictable risks that require active surveillance instead of passive expectation. Gastrointestinal adverse effects are the most frequently reported complication with mycophenolate mofetil. In a retrospective evaluation of 14 dogs treated with mycophenolate mofetil for immune-mediated skin disease, six dogs developed diarrhea, three developed vomiting, and two developed hematochezia, with therapy discontinued in two cases because of diarrhea Ackermann et al., retrospective evaluation of mycophenolate mofetil in 14 dogs. These signs typically emerge within the first two to four weeks of treatment and may coincide with dose escalation. Early detection depends on owner-reported stool frequency and consistency, which should be solicited at each recheck instead of left to spontaneous reporting.

Secondary bacterial pyoderma is a common complication during induction, particularly when glucocorticoids and adjunctive agents are used together. The distinction between active immune-mediated lesions and infected lesions can be difficult because both produce crusts, pustules, and erosions. Cytology of intact pustules and impression smears of crust edges should be performed at every recheck. Neutrophils with intracellular bacteria confirm infection and warrant systemic antibiotics, but the clinician must remember that the underlying immunosuppressive protocol continues unchanged.

Hepatotoxicity and myelosuppression occur less often with mycophenolate mofetil than with azathioprine, but they remain possible Ackermann et al., retrospective evaluation of mycophenolate mofetil in 14 dogs. Serial biochemistry and complete blood counts are the only reliable detection methods. A rising alanine aminotransferase or falling neutrophil count should trigger dose reduction or a switch to an alternative adjunctive agent instead of watchful waiting.

Common Diagnostic Errors

The most frequent error in managing suspected immune-mediated skin disease is initiating immunosuppressive therapy before infectious causes are excluded. Demodicosis, dermatophytosis, and bacterial pyoderma can mimic every pattern described in this article. Skin scrapings, trichography, cytology, and fungal culture must be completed before glucocorticoids are dispensed. This rule holds even when the clinical picture appears classic for pemphigus foliaceus.

A second error is overinterpreting a single positive antinuclear antibody titre. The experimental model of canine systemic lupus erythematosus produced antinuclear antibody titres above 1:128 in all affected dogs, but positive titres also occur in dogs with other inflammatory diseases and in some healthy dogs Choi et al., development of canine systemic lupus erythematosus model. The titre supports a diagnosis of systemic lupus erythematosus only when accompanied by compatible clinical signs and ideally histopathologic confirmation.

A third error is biopsying lesions that have been altered by topical treatment or ruptured by the patient. Crusts that have been removed, pustules that have ruptured, and ulcers that have become secondarily infected all produce nonspecific histopathologic findings. The biopsy should target intact pustules or early lesions, and the clinician should mark these sites clearly for the pathologist.

Evidence Limitations and Expert Disagreement

The evidence base for canine immune-mediated skin disease consists largely of retrospective case series and expert opinion. Prospective randomised trials comparing induction protocols are lacking. The retrospective study of mycophenolate mofetil reported complete remission in eight of 14 dogs and partial remission in two, but the mean time to remission was 5.7 weeks, which is slower than many clinicians expect with glucocorticoid monotherapy Ackermann et al., retrospective evaluation of mycophenolate mofetil in 14 dogs. Whether this delay reflects the drug's mechanism or the severity of the cases treated is unknown.

Expert opinion differs on the speed of glucocorticoid tapering. Some clinicians advocate rapid reduction over four to six weeks to minimize adverse effects, while others prefer slower tapering over several months to reduce relapse risk. The relapse rate reported in juvenile sterile granulomatous dermatitis and lymphadenitis was one of 10 dogs with a three to eight week taper, but this condition may not represent the broader immune-mediated disease population Weingart et al., juvenile sterile granulomatous dermatitis and lymphadenitis in the dog. Neither approach has been tested head to head.

Consensus statements from the American College of Veterinary Internal Medicine provide structured guidance on diagnosis and monitoring, but they acknowledge that many recommendations rest on low-quality evidence ACVIM consensus statements. Clinicians should treat these documents as frameworks for decision-making instead of prescriptive protocols.

Referral and Escalation Criteria

Referral to a veterinary dermatologist or internal medicine specialist is warranted when the diagnosis remains uncertain after biopsy, when lesions progress despite appropriate induction therapy, or when adverse effects limit the use of first-line agents. A dermatopathologist should review biopsy specimens when the initial histopathology report is nondescript or when the clinical picture and histopathology conflict.

Laboratory involvement extends beyond routine biochemistry. Antinuclear antibody testing, direct immunofluorescence, and specialised immunohistochemistry may require referral laboratories with established reference intervals. Results should be interpreted in the context of the individual patient, not as standalone diagnostic tests.

Regulatory reporting is rarely required for immune-mediated skin disease in dogs. The World Organization for Animal Health terrestrial standards do not list canine autoimmune dermatitis as a notifiable condition WOAH terrestrial animal health standards. However, clinicians should remain alert to unusual clusters of skin disease that might indicate an emerging infectious or environmental cause, and local veterinary authorities should be contacted if such a pattern appears.

Frequently Asked Questions

How Should I Manage Immune-Mediated Skin Disease When Biopsy or Advanced Diagnostics Are Unavailable?

When histopathology is not accessible, base the working diagnosis on signalment, lesion pattern, cytology, and response to therapy. Exclude infectious causes first, particularly bacterial pyoderma, dermatophytosis, and demodicosis, using cytology and skin scrapings. Perform a therapeutic trial with ectoparasiticide and antibiotic therapy before committing to immunosuppression. If lesions progress despite these measures, a presumptive diagnosis of immune-mediated disease may justify a cautious glucocorticoid trial with close monitoring. Document the diagnostic limitations clearly in the medical record and revisit the diagnosis if the response is atypical. Referral for biopsy remains the preferred path whenever feasible, as empirical immunosuppression carries risks of unrecognized infection or neoplasia.

What Are the Cost Considerations for Long-Term Immunosuppressive Therapy?

Immunosuppressive protocols generate recurring costs from medications, monitoring bloodwork, and recheck consultations. Glucocorticoids are inexpensive, but steroid-sparing agents such as mycophenolate mofetil add substantial monthly expense. A retrospective evaluation of mycophenolate mofetil in 14 dogs reported gastrointestinal adverse events in six cases, with two dogs discontinuing therapy because of diarrhea, underscoring that cost must include management of potential drug reactions. Clients should receive a written estimate covering induction, tapering, and at least six months of maintenance. Discuss contingency plans for relapse, since additional workup and dose adjustments increase expenditure. Pet insurance may offset some costs, and referral to a specialty hospital can provide access to clinical trials or financial assistance programs.

How Do I Explain the Diagnosis and Treatment Plan to a Client Who Is Reluctant to Pursue Aggressive Therapy?

Frame the discussion around the immune system attacking the skin and explain that immunosuppressive drugs do not cure the disease but control it. Use the analogy of a thermostat that needs adjustment instead of a short course of antibiotics. Clarify that untreated disease causes progressive discomfort, secondary infection, and potentially systemic involvement. Present the monitoring schedule as a safety measure, not an optional extra. Acknowledge client concerns about steroid side effects and describe how steroid-sparing agents can reduce those risks. Provide written instructions and a contact number for concerns. If the client declines recommended therapy, document the discussion and offer palliative options while maintaining an open door for revisiting treatment decisions.

What Records Should I Maintain for a Dog on Long-Term Immunosuppression?

Maintain a problem list that includes the diagnosis, date of confirmation, and all medications with doses and adjustment dates. Record body weight at every visit, since dose calculations depend on accurate weight. Document each recheck examination with lesion descriptions, preferably using photographs or a body map. Log all bloodwork results in a format that allows trend identification, particularly for hematology and biochemistry parameters. Note any adverse events, their timing relative to drug administration, and the action taken. Record client communications about medication administration and observed side effects. These records support rational tapering decisions and provide defensible documentation if complications arise.

When Should I Consider Referral to a Veterinary Dermatologist?

Refer when the diagnosis is uncertain after initial workup, when lesions fail to respond to appropriate induction therapy within the expected timeframe, or when repeated relapses occur during tapering. Refer also when the patient experiences significant adverse drug effects that complicate management, or when the clinical picture suggests a rare condition such as juvenile sterile granulomatous dermatitis and lymphadenitis, which requires specific histopathologic confirmation and has a distinct age distribution. Dermatologists offer advanced diagnostics including direct immunofluorescence, specialized culture techniques, and access to newer therapeutic agents. Early referral may reduce overall cost by shortening the diagnostic odyssey and preventing complications from prolonged inappropriate therapy.

How Does the Approach Differ in Young Puppies Compared to Adult Dogs?

Juvenile patients present unique challenges. Immune-mediated skin disease in puppies is uncommon, and infectious causes such as demodicosis, dermatophytosis, and juvenile cellulitis must be prioritized. Juvenile sterile granulomatous dermatitis and lymphadenitis typically affects dogs between 8 and 36 weeks of age, with fever, lymphadenomegaly, and facial lesions, and responds to glucocorticoid therapy tapered over several weeks. Growth concerns influence drug selection, as chronic glucocorticoid use can impair skeletal development. Monitor puppies more frequently for weight gain, growth parameters, and vaccine responses. Client education must emphasize that immunosuppression may affect the puppy's ability to complete routine vaccination schedules, and discuss the risk-benefit balance with the owner before starting therapy.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Use of mycophenolate mofetil to treat immune-mediated skin disease in 14 dogs - a retrospective evaluation.. 2017.
• Development of canine systemic lupus erythematosus model.. 2004.
• [[Juvenile sterile granulomatous dermatitis and lymphadenitis in the dog].](https://pubmed.ncbi.nlm.nih.gov/21452146/). 2011.
• Contribution of <i>In Vivo</i> and Organotypic 3D Models to Understanding the Role of Macrophages and Neutrophils in the Pathogenesis of Psoriasis.. 2017.
• Allergens causing atopic diseases in canine.. 2002.
• Regional distribution of ten common skin diseases in dogs.. 1989.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Feline Immune-Mediated Disease: Diagnostic Approach and Management
• Canine Immune-Mediated Polyarthritis: Diagnostic Approach and Management
• Canine Immune-Mediated Myositis: Diagnostic and Therapeutic Approach
• Canine Immune-Mediated Arthropathy: Diagnostic and Management Framework
• Canine Immune-Mediated Hemolytic Anemia: Diagnostic and Management Framework

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.